These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22300941)

  • 1. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.
    Tognon R; Gasparotto EP; Neves RP; Nunes NS; Ferreira AF; Palma PV; Kashima S; Covas DT; Santana M; Souto EX; Zanichelli MA; Simões BP; de Souza AM; Castro FA
    J Hematol Oncol; 2012 Feb; 5():2. PubMed ID: 22300941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
    Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
    Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
    Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of JAK2
    Latagliata R; Polverelli N; Tieghi A; Palumbo GA; Breccia M; Sabattini E; Villari L; Riminucci M; Valli R; Catani L; Alimena G; Ottaviani E; Fama A; Martinelli G; Perricone M; Spinsanti M; Cavo M; Vianelli N; Palandri F
    Hematol Oncol; 2018 Feb; 36(1):269-275. PubMed ID: 28509339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
    Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
    Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.
    Kreft A; Kindler T; Springer E; Kirkpatrick CJ
    Virchows Arch; 2011 Nov; 459(5):521-7. PubMed ID: 22006129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases.
    Tognon R; Gasparotto EP; Leroy JM; Oliveira GL; Neves RP; Carrara Rde C; Kashima S; Covas DT; Santana M; Souto EX; Zanichelli MA; Velano CE; Simões BP; Alberto FL; Miyashiro K; de Souza AM; Amarante-Mendes GP; de Castro FA
    J Clin Pathol; 2011 Jan; 64(1):75-82. PubMed ID: 21045235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
    Moliterno AR; Williams DM; Rogers O; Isaacs MA; Spivak JL
    Exp Hematol; 2008 Nov; 36(11):1480-6. PubMed ID: 18723264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Moura LG; Tognon R; Nunes NS; Rodrigues LC; Ferreira AF; Kashima S; Covas DT; Santana M; Souto EX; Perobelli L; Simões BP; Dias-Baruffi M; Castro FA
    J Clin Pathol; 2016 Oct; 69(10):926-9. PubMed ID: 27402956
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
    Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
    Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
    J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
    Gángó A; Mózes R; Boha Z; Kajtár B; Timár B; Király PA; Kiss R; Fésüs V; Nagy N; Demeter J; Körösmezey G; Borbényi Z; Marton I; Szőke A; Masszi T; Farkas P; Várkonyi J; Plander M; Pósfai É; Egyed M; Pál K; Radványi G; Hamed A; Csomor J; Matolcsy A; Alpár D; Bödör C
    Leuk Res; 2018 Feb; 65():42-48. PubMed ID: 29306106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.